15 Investor presentation First six months of 2020 R&D milestones for 2020 and Q1 Diabetes Obesity Biopharm Other serious chronic diseases Project Ozempic® Xultophy® Icodec Rybelsus® Semaglutide Obesity AM833 (Amylin) AM833 + Semaglutide Obesity projects Somapacitan (AGHD) Semaglutide NASH PCSK9i Staten Ziltivekimab Q2 2020 ✓ EU commission decision ✓ Japan PMDA decision ✓Phase 3 results ✓Phase 2 results ✓Phase 1 results ✓Phase 1 results (terminated) ✓Phase 2 results ✓Phase 1 results ✓Phase 1 initiation 1 Expected to be published in the given quarter or in the subsequent quarterly company announcement; Note: Trial initiati FGF-21 in NASH project has moved Sema: Semaglutide; GIP: Gastric inhibitory polypeptide; EU: European Union; JP PMDA: Japanese Pharmaceutical and Me alcoholic steatohepatitis
Download PDF file